UNSPSC 51191544: Cyclothiazide

This classification denotes a thiazide diuretic with the molecular formula C14H16ClN3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P71U09G5BW, chemically known as 6-chloro-3,4-dihydro-3-(norbornen-2-yl)-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide but generally known as cyclothiazide, which bears US NIH Compound Identifier 2910. European Medicines Agency schedules Cyclothiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06864MIG.

UNSPSC 51191544 Cyclothiazide is a Commodity code that in recent state and local procurement activity covers pharmaceutical and chemical products supplied to public facilities—though the recent solicitations tagged under this code show a marked mismatch between the nominal commodity (cyclothiazide, a diuretic medication) and the work actually being bought. The City of Meriden, Connecticut, recently solicited sodium bisulfite, a water treatment chemical unrelated to the code's pharmaceutical scope. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a broader RFP for generic multi-source pharmaceuticals and over-the-counter products to be distributed across participating state and local government facilities. The issuing bodies show a mix of municipal water utilities and state-coordinated cooperative purchasing programs, with MMCAP's multi-state vehicle indicating coordination across participating jurisdictions. Insurance and compliance requirements are substantial—the Meriden bid required $1 million to $2 million in general liability coverage and performance and payment bonds; the MMCAP RFP mandated $5 million in commercial general liability per occurrence, $2 million in network security and privacy liability, and $2 million in professional liability, plus cGMP certification and Drug Supply Chain Security Act compliance.

Recent activity spans Connecticut and a multi-state region through MMCAP, which encompasses Minnesota and Oregon. The City of Meriden's IFB for sodium bisulfite closed July 29, 2026, for municipal water pollution control operations priced on a unit-cost basis. MMCAP's RFP, due March 26, 2026, sought manufacturers to supply identified pharmaceutical products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with products required in the marketplace by May 15, 2026, and the resulting contracts effective July 1, 2026; evaluation weighted price competitiveness at 75 percent, with fixed pricing, administrative-fee compliance, EDI capability, and pricing-format flexibility each weighted between 5 and 10 percent. No specific award values or budget ranges were disclosed in either solicitation. The code shows limited relevant recent activity—the two opportunities present are geographically sparse and the Meriden solicitation falls outside the pharmaceutical scope the code nominally addresses.